Evidence map›Paper›PMID 28356132›Full record

ArticleChinese journal of cancer2017

Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.

Wenchu Wang, Lihui Wang, Atsushi Mizokami, Junlin Shi, Chunlin Zou, Jinlu Dai, Evan T Keller, Yi Lu, Jian Zhang

Open access · goldAbstract read
In one paragraph

Article in Chinese journal of cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 86 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Wenchu WangCenter for Translational Medicine, Guangxi Medical University, 12th Floor, Medical Science Research Building, No. 22 Shuangyong Road, Nanning, Guangxi, 530021, P. R. China.
Lihui WangCenter for Translational Medicine, Guangxi Medical University, 12th Floor, Medical Science Research Building, No. 22 Shuangyong Road, Nanning, Guangxi, 530021, P. R. China.
Atsushi MizokamiDepartment of Urology, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, 920-1192, Japan.
Junlin ShiCenter for Translational Medicine, Guangxi Medical University, 12th Floor, Medical Science Research Building, No. 22 Shuangyong Road, Nanning, Guangxi, 530021, P. R. China.
Chunlin ZouCenter for Translational Medicine, Guangxi Medical University, 12th Floor, Medical Science Research Building, No. 22 Shuangyong Road, Nanning, Guangxi, 530021, P. R. China.
Jinlu DaiDepartment of Urology and Pathology, School of Medicine, University of Michigan, Ann Arbor, MI, 48109, USA.
Evan T KellerDepartment of Urology and Pathology, School of Medicine, University of Michigan, Ann Arbor, MI, 48109, USA.
Yi LuCenter for Translational Medicine, Guangxi Medical University, 12th Floor, Medical Science Research Building, No. 22 Shuangyong Road, Nanning, Guangxi, 530021, P. R. China. luyi5555@hotmail.com.
Jian ZhangCenter for Translational Medicine, Guangxi Medical University, 12th Floor, Medical Science Research Building, No. 22 Shuangyong Road, Nanning, Guangxi, 530021, P. R. China. jianzhang008@hotmail.com.
Guangxi Medical University · CNUniversity of Michigan–Ann Arbor · USKanazawa University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe chemoresistance of prostate cancer (PCa) is invariably associated with the aggressiveness and metastasis of this disease. New emerging evidence indicates that the epithelial-to-mesenchymal transition (EMT) may play pivotal roles in the development of chemoresistance and metastasis. As a hallmark of EMT, E-cadherin is suggested to be a key marker in the development of chemoresistance. However, the molecular mechanisms underlying PCa chemoresistance remain unclear. The current study aimed to explore the association between EMT and chemoresistance in PCa as well as whether changing the expression of E-cadherin would affect PCa chemoresistance.

methodsParental PC3 and DU145 cells and their chemoresistant PC3-TxR and DU145-TxR cells were analyzed. PC3-TxR and DU145-TxR cells were transfected with E-cadherin-expressing lentivirus to overexpress E-cadherin; PC3 and DU145 cells were transfected with small interfering RNA to silence E-cadherin. Changes of EMT phenotype-related markers and signaling pathways were assessed by Western blotting and quantitative real-time polymerase chain reaction. Tumor cell migration, invasion, and colony formation were then evaluated by wound healing, transwell, and colony formation assays, respectively. The drug sensitivity was evaluated using MTS assay.

resultsChemoresistant PC3-TxR and DU145-TxR cells exhibited an invasive and metastatic phenotype that associated with EMT, including the down-regulation of E-cadherin and up-regulation of Vimentin, Snail, and N-cadherin, comparing with that of parental PC3 and DU145 cells. When E-cadherin was overexpressed in PC3-TxR and DU145-TxR cells, the expression of Vimentin and Claudin-1 was down-regulated, and tumor cell migration and invasion were inhibited. In particular, the sensitivity to paclitaxel was reactivated in E-cadherin-overexpressing PC3-TxR and DU145-TxR cells. When E-cadherin expression was silenced in parental PC3 and DU145 cells, the expression of Vimentin and Snail was up-regulated, and, particularly, the sensitivity to paclitaxel was decreased. Interestingly, Notch-1 expression was up-regulated in PC3-TxR and DU145-TxR cells, whereas the E-cadherin expression was down-regulated in these cells comparing with their parental cells. The use of γ-secretase inhibitor, a Notch signaling pathway inhibitor, significantly increased the sensitivity of chemoresistant cells to paclitaxel.

conclusionThe down-regulation of E-cadherin enhances PCa chemoresistance via Notch signaling, and inhibiting the Notch signaling pathway may reverse PCa chemoresistance.

Indexed as

Down-RegulationDrug Resistance, NeoplasmAnimalsAntigens, CDCadherinsCell Line, TumorCell MovementEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansMaleMicePaclitaxelProstatic NeoplasmsReceptors, NotchSignal TransductionAntigens, CDCadherinsCDH1 protein, humanPaclitaxelReceptors, NotchChemoresistanceE-cadherinEpithelial-to-mesenchymal transitionNotch signalingProstate cancer

Identifiers

PMID28356132
PMCPMC5372329
OpenAlexW2599277457

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.